Cell line-derived xenograft (CDX) models use human tumor cell lines implanted into immunodeficient mice. Studies can measure tumor growth, treatment response and pharmacodynamic changes. MuriPhys supports subcutaneous and orthotopic implantation, IV, IM and SC dosing, caliper measurements and in vivo imaging. We select the cell line, mouse strain and endpoints according to the treatment question.
Models & cell lines
Solid Tumor Xenograft Models
Breast Cancer
MDA-MB-231 (TNBC, highly metastatic)
MCF-7 (ER+, PR+, luminal A subtype)
T47D (ER+, PR+, luminal B subtype)
Non-Small Cell Lung Cancer (NSCLC)
A549 (KRAS mutant, adenocarcinoma)
H1975 (EGFR T790M mutant, resistant to 1st-gen TKIs)
H1299 (p53-null, metastatic potential)
Colorectal Cancer
HCT116 (KRAS mutant, MSI+)
SW620 (metastatic colorectal cancer model)
HT-29 (BRAF V600E mutant, chemoresistant)
Pancreatic Cancer
PANC-1 (KRAS mutant, mesenchymal phenotype)
MiaPaCa-2 (KRAS mutant, p53 mutant, highly aggressive)
AsPC-1 (metastatic potential)
Brain Tumor
U87MG (glioblastoma, limited invasion capacity)
U251 (astrocytoma-derived, high proliferation)
DAOY (medulloblastoma, pediatric brain cancer)
Prostate Cancer
LNCaP (androgen-sensitive, PSA-producing)
DU145 (androgen-independent, metastatic potential)
PC-3 (highly aggressive, androgen receptor-negative)
Hematologic Cancer Xenograft Models
Leukemia Xenograft Models
Acute Myeloid Leukemia (AML)
- MV4-11 (FLT3-ITD mutant)
- HL-60 (differentiation-sensitive, ATRA-responsive)
- KG-1 (primitive leukemic stem cell-like)
Acute Lymphoblastic Leukemia (ALL)
- Nalm-6 (B-ALL, p53 wild-type)
- MOLT-4 (T-ALL, highly proliferative)
Chronic Myeloid Leukemia (CML)
- K562 (BCR-ABL1 fusion, imatinib-sensitive)
Lymphoma Xenograft Models
Diffuse Large B-Cell Lymphoma (DLBCL)
- SU-DHL-4 (ABC subtype, NF-κB pathway activation)
- OCI-LY3 (activated B-cell-like, MYD88 mutant)
Hodgkin Lymphoma (HL) Models
- L428 (classical HL, CD30+)
- KM-H2 (brentuximab vedotin-sensitive)
Multiple Myeloma Xenograft Models
- MI-8226 (bortezomib-sensitive, IgG lambda secretion)
Drug administration & repeat dosing
We specialize in the following routes of administration:
Administration routes include intravenous (IV), intramuscular (IM), subcutaneous (SC), intrathecal (IT), intraperitoneal (IP), oral gavage and topical delivery, with slow or continuous infusion where appropriate.
Repeat dosing can be scheduled to assess treatment effects over time.
Cell-line quality control
Cell-line quality control includes mycoplasma testing to identify contamination. The testing plan, cell identity checks and acceptance criteria are defined for the study and documented with the work.
Discuss the tumor model, treatment strategy, readouts and study stage with our oncology team. We will work with you to define the methods, controls, deliverables, timing and budget.


